ABSTRACT
Typhoid fever is an infectious disease among humans caused by the bacterium
Salmonella typhi. With the high Multi-Drug Resistance (MDR) of Salmonella
typhi, selecting the right antibiotic is a factor that must be considered in addition
to cost constraints. Therefore, cost-effectiveness is needed. This study aims to
determine the cost-effectiveness of typhoid fever patients using ceftriaxone and
cefixime antibiotics. The data used are retrospective, and the sampling was done
by purposive sampling. This study was conducted at Berkah Pandeglang
Regional Hospital. Sample in this study, namely typhoid fever patients of the
period 2020-2021, who meet the inclusion and exclusion criteria. In this study,
16 samples were obtained. The results of this study showed that the total average
direct medical costs for the ceftriaxone group were IDR 78.632.500 In contrast,
the cefixime group was IDR 75.527.300. The ACER value of typhoid fever
patients who used Ceftriaxone + cefixime was IDR 91,646.27, Ceftriaxone was
IDR 77,463.89, and cefixime was IDR 88,027.15. The patients with typhoid fever
who used Ceftriaxone were more cost-effective than those who used Cefixime.
Keywords: Typhoid Fever; Ceftriaxone; Cefixime; Cost-Effectiveness Analysis